XML 17 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
SALE OF GVAX CANCER VACCINE ASSETS (Details) (Aduro, Asset purchase agreement, USD $)
In Millions, unless otherwise specified
0 Months Ended
Jan. 31, 2013
SALE OF GVAX CANCER VACCINE ASSETS  
Cash payment received $ 1.0
Royalty rate as a percentage of net sales 2.00%
Period from the first commercial sale of each GVAX product for which royalty is payable 7 years
Additional amount that the entity is entitled to receive as a percentage of all amounts received from milestone and royalty payments from The John P. Hussman Foundation 50.00%
Maximum
 
SALE OF GVAX CANCER VACCINE ASSETS  
Aggregate amount of royalties and milestone payments receivable 162.0
Milestone payment upon achievement of threshold in net sales of GVAX-pancreas products
 
SALE OF GVAX CANCER VACCINE ASSETS  
Aggregate amount receivable, if regulatory milestones are successfully achieved 2.0
Threshold amount of net sales of products upon achievement of which milestone payments will be receivable 10.0
Milestone payment upon achievement of threshold in net sales of GVAX-pancreas products | Maximum
 
SALE OF GVAX CANCER VACCINE ASSETS  
Aggregate amount receivable, if regulatory milestones are successfully achieved 50.0
Milestone payment upon achievement of threshold in net sales of GVAX-prostate products
 
SALE OF GVAX CANCER VACCINE ASSETS  
Aggregate amount receivable, if regulatory milestones are successfully achieved 2.0
Threshold amount of net sales of products upon achievement of which milestone payments will be receivable 10.0
Milestone payment upon achievement of threshold in net sales of GVAX-prostate products | Maximum
 
SALE OF GVAX CANCER VACCINE ASSETS  
Aggregate amount receivable, if regulatory milestones are successfully achieved $ 50.0